Deals

Eli Lilly Completes Acquisition of AtaiBeckley for up to USD 3.8 Billion – Deal Secures BPL‑003 Rapid‑Acting Neuroplastogen for Treatment‑Resistant Depression
AtaiBeckleyEli Lilly

Eli Lilly Completes Acquisition of AtaiBeckley for up to USD 3.8 Billion – Deal Secures BPL‑003 Rapid‑Acting Neuroplastogen for Treatment‑Resistant Depression

Eli Lilly (NYSE: LLY) announced the successful completion of its acquisition of AtaiBeckley Inc., a clinical‑stage biopharmaceutical company developing rapid‑acting neuroplastogens for mental health conditions. Lilly had announced the transaction…

Diagens Biotechnology and AntAngelMed Forge Three‑Year Pact on Medical Imaging AI – iMedImage Platform Anchors Zhejiang's Provincial "Digital and Intelligent Imaging" Build‑Out

Diagens Biotechnology and AntAngelMed Forge Three‑Year Pact on Medical Imaging AI – iMedImage Platform Anchors Zhejiang’s Provincial “Digital and Intelligent Imaging” Build‑Out

Boji Medical and Zhejiang Maiyata Sign Strategic Partnership – Leading China CRO Joins Microbiome Innovator to Advance Live Biotherapeutic Products

Boji Medical and Zhejiang Maiyata Sign Strategic Partnership – Leading China CRO Joins Microbiome Innovator to Advance Live Biotherapeutic Products

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
GSK Secures Worldwide Exclusive Rights to Empirico’s EMP‑012, a First‑in‑Class siRNA for COPD
EmpiricoGlaxoSmithKline

GSK Secures Worldwide Exclusive Rights to Empirico’s EMP‑012, a First‑in‑Class siRNA for COPD

WuXi AppTec Signs Dual MoUs with NEOM and Saudi Ministry of Health to Advance Localized Drug Development
CRO / CMO / CDMOHKG: 2359

WuXi AppTec Signs Dual MoUs with NEOM and Saudi Ministry of Health to Advance Localized Drug Development

Qyuns Therapeutics Partners with Roche for Global Rights to Long‑Acting Bispecific Antibody QX031N
Auto-immuneHKG: 2509

Qyuns Therapeutics Partners with Roche for Global Rights to Long‑Acting Bispecific Antibody QX031N

Fosun Pharmaceutical Announces Spin‑Off and HK Listing of Adgenvax
Fosun Adgenvax BiopharmaceuticalFosun Pharmaceutical

Fosun Pharmaceutical Announces Spin‑Off and HK Listing of Adgenvax

Show More